Skip to main content

Table 1 Patient characteristics of the discovery cohort

From: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Characteristics No. (%)
No. of patients 519
Median age, years (range) 64 (18–92)
Sex
 Male 300 (57.8)
 Female 219 (42.2)
Cancer type
 Bladder cancer 27 (5.2)
 Esophagogastric cancer 40 (7.7)
 Head and neck cancer 10 (1.9)
 Melanoma 148 (28.5)
 Non-small-cell lung cancer 294 (56.6)
Drug class
 CTLA-4, monotherapy 142 (27.4)
 PD-(L)1, monotherapy 320 (61.7)
 CTLA-4 + PD-(L)1, combination therapy 57 (11.0)
Best overall response
 CR/PR 126 (24.3)
 SD 137 (26.4)
 PD 252 (48.6)
 NE 4 (0.8)
Durable clinical benefit
 DCB 165 (31.8)
 NDB 330 (63.6)
 NE 24 (4.6)
Median TMB, Mutation/Mb (IQR) 7.14 (3.77–13.24)
TET1 status
 Mutant 23 (4.4)
 Wildtype 496 (95.6)
  1. Abbreviations: CR complete response, CTLA-4 cytotoxic T-cell lymphocyte-4, DCB durable clinical benefit, IQR interquartile range, Mb megabase, NDB no durable benefit, NE not evaluable, PD progressive disease, PD-(L)1 programmed cell death-1 or programmed death-ligand 1, PR partial response, SD stable disease, TMB tumor mutational burden